Progenics Pharmaceuticals
Tarrytown, New York, 10591, United States
NCT Number: NCT01367600
This study is an open-label extension allowing patients who have completed Protocol MNTX 301 to continue to receive SC MNTX.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Tarrytown, New York, 10591, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 3 months
To provide access to continued treatment with MNTX administered SC, to patients who completed Progenics' MNTX 301.
Time frame: 3 months
To provide access to continued treatment with MNTX administered SC, to patients who completed Progenics' MNTX 301.
Time frame: 3 months
To provide access to continued treatment with MNTX administered SC, to patients who completed Progenics' MNTX 301.
Looking for future studies?
Notify MeBausch Health Americas, Inc.
Industry
A Three-Month Open-Label Treatment Extension of Protocol MNTX 301
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05365919
Behavior, Communication
Stockholm, Sweden
View Trial DetailsNCT04612738
Advance Care Planning, Advance Directives
Athens, Alabama, United States
View Trial DetailsNCT04257227
Anxiety Disorders, Behavior
Ottawa, Ontario, Canada
View Trial DetailsNCT04950608
Cancer Terminal, Cancer-related Problem/Condition
Danvers, Massachusetts, United States
View Trial Details